Cellestia Biotech

Cellestia Biotech SA, supported by Innovaud, is a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway. CB-103 is a novel, first-in-class, oral pan-NOTCH inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.
Cellestia Biotech AG was founded in 2014 as a spin-off from Ecole Polytechnique Fédérale de Lausanne, EPFL and is managed by a high-calibre team of academic and industry professionals.

Principal

Female Founder News

The spotlight shines the brightest on the trailblazers – startup founders who dare to disrupt, create, and lead. In our monthly 'Female Founder News', we focus on the achievements of female entrepreneurs who are shaping industries while leaving a mark on the Swiss entrepreneurial scene.
The May edition is out.

Register for more services

Partners

Contributors